Basilar Migraine (Migraine with Brainstem Aura): Why You Were Told No Triptans — and What the Evidence Actually Says

A woman in her mid-thirties came to my clinic last year carrying a folder of normal test results and one question: “Am I having small strokes?” Two or three times a year, for almost a decade, the same thing would happen. Zigzag lights in both eyes, then her speech would slur, then the room would tilt and she would see two of everything for about twenty minutes. A headache would take over the rest of the day. An emergency doctor had written basilar migraine on a discharge sheet in 2019, and since then three different clinicians had refused to give her anything for the attacks because of that phrase.

Here is what I told her, and it is the short answer to the question that probably brought you here. What she has is now called migraine with brainstem aura. It is a subtype of migraine, not a warning of imminent stroke, and the absolute ban on triptans she had been living under rests on a theory that has largely been abandoned. That does not mean anything goes. It means the decision should be a weighing of risk with a doctor who knows the evidence, not a contraindication recited off a label written in 1998.

What migraine with brainstem aura actually means

You may have heard three or four names for this: basilar migraine, basilar artery migraine, basilar-type migraine, Bickerstaff syndrome. The current classification dropped all of them, and the reason matters. Those names came from a 1961 hypothesis that the attacks were caused by spasm of the basilar artery. We no longer believe that. The symptoms come from the same slow electrical wave that produces ordinary migraine aura, only it travels across brainstem territory instead of, or in addition to, the visual cortex. Hence the neutral name: migraine with brainstem aura.

The diagnostic bar is higher than most people realize. It requires a typical aura — visual, sensory, or speech and language symptoms — plus at least two fully reversible brainstem symptoms from this list:

• Slurred speech (dysarthria, not word-finding trouble)
• Vertigo — true spinning, not lightheadedness
• Ringing in the ears
• Reduced hearing
• Double vision
• Unsteadiness or ataxia that is not explained by numbness
• A drop in level of consciousness

Two of those. One is not enough, and this is where most of the mislabelling happens — a person has vertigo with their migraine, someone writes “basilar,” and a decade of restricted treatment follows. There are two more requirements: no motor weakness at all (weakness moves you to a different diagnosis), and no symptoms confined to one eye. Each symptom should come on gradually over at least five minutes and clear within an hour, with the headache arriving during the aura or within sixty minutes of it ending.

The four things it gets confused with

A posterior circulation TIA or stroke. This is the one worth getting right. Aura builds — it marches, spreads, and adds symptoms over minutes. A TIA arrives at full strength almost instantly. Aura tends to produce positive phenomena first: zigzags, shimmering, ringing. Ischemia produces loss: a dark field, silence, dead numbness. And aura in someone who has had it for fifteen years looks the same each time and always resolves completely.

Vestibular migraine. Far more common, and the source of most of the confusion. In vestibular migraine, dizziness is the whole story and it can last hours to days. It does not require typical aura alongside it, and it does not require a second brainstem symptom. If dizziness is your only neurological symptom, this is almost certainly your diagnosis — and it is good news, because it comes with none of the treatment restrictions.

Hemiplegic migraine. If there is genuine one-sided weakness, the diagnosis changes, even if every brainstem symptom is also present. The two are managed differently enough that the distinction is worth insisting on.

Inner ear disease and episodic ataxia. Ménière’s disease causes vertigo with hearing loss, but the hearing loss accumulates over years and is usually one-sided. Episodic ataxia type 2 causes attacks of unsteadiness and vertigo that often start in childhood, run in families, and respond to acetazolamide — I have seen it carry a migraine label for twenty years.

Why you were told no triptans

When sumatriptan was approved, nobody knew whether constricting blood vessels in a patient whose attacks were believed to be caused by arterial spasm might tip them into a stroke. So patients with basilar and hemiplegic migraine were excluded from the trials, and the labels were written to exclude them too. Thirty years later the labels still say it — but the reason they say it is that these patients were never studied, not that harm was ever demonstrated.

Two things have changed since. The vasospasm theory has been replaced: we now attribute aura to cortical spreading depression, a wave of electrical change, and the blood flow shifts follow the wave rather than cause it. And a good deal of real-world prescribing has happened anyway. Observational series and registry data in patients with brainstem and hemiplegic aura have not produced the cluster of strokes the theory predicted. Several headache societies now treat this as a relative rather than an absolute contraindication.

What I do in clinic depends on the person in front of me. If someone has no vascular risk factors, a clear decade-long pattern, and nothing else has worked, I will discuss a triptan explicitly as an off-label decision, document the conversation, and start at a low dose. If they smoke, have high blood pressure, high cholesterol, or a family history of early stroke, I do not — and I no longer need to, because two drug classes exist now that did not in the 1990s. Gepants such as ubrogepant and rimegepant block CGRP without constricting anything, and lasmiditan works on a serotonin receptor subtype that has no vascular action. Neither carries the brainstem aura exclusion. For many of my patients with this diagnosis, they have quietly made the whole argument irrelevant.

One caution: this is a conversation to have with your own neurologist, not an instruction to talk a reluctant doctor into a prescription. A physician who declines to prescribe against a label is being reasonable, and the alternatives above give you somewhere better to go than an argument.

Preventing the aura, not just the headache

When the frightening part of an attack is the twenty minutes of slurred speech and double vision, the goal of prevention shifts. Most migraine preventives were tested against headache days, not aura frequency, and the two do not always move together.

Lamotrigine is the outlier here. It does little for migraine pain, but it has the most consistent track record of any drug for reducing aura frequency specifically, which makes it my usual first choice when aura is the main burden. Topiramate is a reasonable alternative with evidence in both. Candesartan is worth knowing about if the first two fail or are not tolerated. Magnesium at 400–600 mg daily is low-risk and sometimes enough on its own in mild cases.

Two non-drug points carry more weight than any of the above. Combined hormonal contraceptives should generally come off the table — the stroke risk in anyone with aura is the one hard rule in this whole discussion, and it applies with more force when the aura is this extensive. And if you smoke, stopping does more for your stroke risk than every preventive combined.

When I stop calling it migraine and order the scan

A long-standing, identical, fully reversible pattern in a healthy young person rarely needs repeat imaging. These are the situations where I image anyway, or send someone to the emergency department:

• The first episode of your life — especially after age 50, when new aura is far more likely to be vascular
• Symptoms that last longer than an hour, or leave anything behind after the attack ends
• Onset that is instantaneous rather than gradual, or a headache that peaks within a minute
• Neck pain or a recent neck injury before the episode, which raises the question of an arterial dissection
• A pattern that has changed — more frequent, longer, or new symptoms added — particularly with vascular risk factors
• Progressive hearing loss on one side, which points away from migraine entirely

The scan I want is an MRI of the brain with vascular imaging of the posterior circulation. A plain CT is close to useless for this territory and a normal one should never end the conversation.

My patient left with lamotrigine, a gepant to take at the first zigzag, and a one-page letter explaining what her diagnosis does and does not mean, so that the next emergency physician would not start from the word basilar. Her attacks are down to two a year. What changed was not a new drug — it was somebody re-examining a label that had been sitting unquestioned in her chart for six years. If your treatment has stalled behind a diagnosis nobody has revisited, that label deserves as much scrutiny as the treatment.

---

Not sure whether your symptoms are aura or something that needs urgent assessment? Download the free headache red-flag checklist — the same list I run through in clinic before I call a headache benign.

Been carrying the same diagnosis for years without improvement? You can talk to a specialist about a second look at the diagnosis itself.

Written by Dr. Tae-Ho Guak, MD, board-certified neurologist. This article is general medical information and not a substitute for individual medical advice. It is not a recommendation to take any medication against its labelling — decisions about triptans, gepants, or preventives in migraine with brainstem aura must be made with your own physician, who knows your vascular risk. If you have sudden neurological symptoms for the first time, or symptoms that do not fully resolve, seek emergency care.